Wall Street Zen upgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a hold rating to a buy rating in a research report report published on Saturday,Wall Street Zen reports.
TXG has been the subject of several other research reports. Argus started coverage on 10x Genomics in a report on Monday, September 28th. They set a “buy” rating and a $110.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of 10x Genomics in a research note on Monday, September 21st. Citigroup raised their price objective on 10x Genomics from $50.00 to $60.00 and gave the company a “hold” rating in a research note on Friday, November 6th. Morgan Stanley lifted their price objective on shares of 10x Genomics from $40.00 to $70.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. Finally, Royal Bank Of Canada assumed coverage on shares of 10x Genomics in a report on Tuesday, September 1st. They set a “sector perform” rating and a $70.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, 10x Genomics currently has a consensus rating of “Hold” and a consensus price target of $68.40.
View Our Latest Analysis on TXG
10x Genomics Price Performance
TXG opened at $54.99 on Friday. 10x Genomics has a fifty-two week low of $15.18 and a fifty-two week high of $102.81. The firm has a market capitalization of $7.16 billion, a PE ratio of -105.75 and a beta of 2.03. The company’s 50-day moving average is $73.77 and its 200 day moving average is $42.74.
10x Genomics (NASDAQ:TXG – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.12. The business had revenue of $150.67 million for the quarter, compared to analysts’ expectations of $147.96 million. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.19%. The firm’s revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.22) EPS. As a group, analysts expect that 10x Genomics will post -0.74 EPS for the current year.
Insider Activity at 10x Genomics
In related news, CEO Serge Saxonov sold 31,000 shares of the stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $62.90, for a total transaction of $1,949,900.00. Following the completion of the transaction, the chief executive officer owned 1,019,249 shares in the company, valued at approximately $64,110,762.10. This represents a 2.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 13,818 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $63.02, for a total transaction of $870,810.36. Following the sale, the insider owned 488,182 shares of the company’s stock, valued at $30,765,229.64. This trade represents a 2.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 190,333 shares of company stock worth $12,604,970. 8.84% of the stock is owned by company insiders.
Institutional Trading of 10x Genomics
Hedge funds have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC grew its position in shares of 10x Genomics by 29.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 934 shares of the company’s stock valued at $84,000 after acquiring an additional 215 shares during the period. GAMMA Investing LLC raised its holdings in shares of 10x Genomics by 8.7% in the 3rd quarter. GAMMA Investing LLC now owns 4,668 shares of the company’s stock worth $422,000 after purchasing an additional 374 shares during the period. Arizona State Retirement System raised its holdings in shares of 10x Genomics by 1.5% in the 2nd quarter. Arizona State Retirement System now owns 29,223 shares of the company’s stock worth $1,120,000 after purchasing an additional 430 shares during the period. Steward Partners Investment Advisory LLC lifted its stake in 10x Genomics by 240.6% in the third quarter. Steward Partners Investment Advisory LLC now owns 671 shares of the company’s stock valued at $61,000 after purchasing an additional 474 shares during the last quarter. Finally, Carolina Wealth Advisors LLC purchased a new position in 10x Genomics in the third quarter valued at approximately $46,000. Institutional investors own 84.68% of the company’s stock.
10x Genomics Company Profile
10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.
Further Reading
- Five stocks we like better than 10x Genomics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
